Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Depreciation and Depletion: 2022-2025

Historic Depreciation and Depletion for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $120,000.

  • Axsome Therapeutics' Depreciation and Depletion fell 8.40% to $120,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $518,000, marking a year-over-year decrease of 3.36%. This contributed to the annual value of $532,000 for FY2024, which is 15.90% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Depreciation and Depletion is $120,000, which was down 0.00% from $120,000 recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Depreciation and Depletion peaked at $149,000 during Q1 2025, and registered a low of $37,000 during Q1 2022.
  • In the last 3 years, Axsome Therapeutics' Depreciation and Depletion had a median value of $131,000 in 2024 and averaged $125,455.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first soared by 143.24% in 2023, then decreased by 14.29% in 2025.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' Depreciation and Depletion stood at $85,000 in 2022, then soared by 56.47% to $133,000 in 2023, then declined by 3.01% to $129,000 in 2024, then decreased by 8.40% to $120,000 in 2025.
  • Its Depreciation and Depletion stands at $120,000 for Q3 2025, versus $120,000 for Q2 2025 and $149,000 for Q1 2025.